Starr Fintech Global SFG Desk Research

A-Share · Pre-Market

A-Share Pre-Market Brief | 2026-11-16 (Monday)

Mon A-Share Pre-Market · 10 tables Asia/Shanghai

Machine-translated from the Chinese original. In case of any discrepancy, the Chinese version prevails.

Single-name entries 15

Show 3 more
13 禾元生物 688765 B
科创板(-U 未盈利,±20%) Unverified
37
只看不买
14 游族网络 002174 C+
深主板 Unverified
32
Pass
15 北纬科技 002148 C
深主板 Unverified
20
Pass(仅作情绪风向标)

Scores are a subjective ordinal scale; gaps within a band carry no ranking meaning

Time window: after the close on Friday 2026-11-13 at 15:00 → 2026-11-16 07:30. Friday's recap see reports/a-share/2026-11-13-recap.md (ice point: ChiNext -3.32%, nearly 4,500 decliners, limit-up advancement rate only 19%). Friday close: Shanghai Composite 3634.35 (-0.59%), ChiNext 2426.08 (-3.32%).

0. Today's One-Line Summary

The single hardest new catalyst of the weekend is the landing of the medical-insurance "dual catalogues" (51 first-class innovative drugs, a record high; CAR-T entering medical insurance for the first time; 19 A-share pharma companies disclosing concentratedly on the evening of 11-15), superimposed on the macro warmth from the first meeting of the trade council under the China-US economic and trade consultation mechanism (11-13), which — against Friday's ice point — creates the opening conditions for a "news-driven rebound"; but the overseas computing-power chain is the biggest headwind — NVIDIA CEO Jensen Huang resigned on 11-12 and the stock fell -13% for the full week, SOX -3.43% on Friday, AMD down over 8%, and with NVDA earnings due this Tuesday (US Eastern 11-17), funds will most likely keep de-risking into it, so A-share computing hardware such as optical modules / PCB / memory remains under pressure on Monday. Driver types: policy (medical insurance) + overseas industry (NVIDIA event, negative) + orders (Yuanjie RMB 1.744 billion) + event (Iran's 11-15 attack on the US military base in Bahrain). Likely fund destinations: innovative drugs (new catalyst + oversold low position), oil & gas defense (event + dividends, the only validated direction on Friday), gaming / AI short drama (Friday's only survivor + BLG's championship fermenting over the weekend). Pre-market state judgment: a lower or flat open is most likely; the strength of the rebound hinges on auction absorption in innovative drugs and whether the Shanghai Composite can reclaim 3647; do not chase a reflexive bounce in the computing-power chain — treat the first positive candle after the ice point purely as an observation window.

1. News Overview

No. Time Source Title Type Branch Impact Link
1 11-14 National Healthcare Security Administration / Qiushi 2026 medical insurance + commercial insurance innovative-drug "dual catalogues" released: 107 additions, 51 first-class innovative drugs a record high; 2 commercial-insurance drugs moved into basic medical insurance Policy Innovative drugs S- Qiushi.com
2 11-15 evening Company announcements 19 A-share pharma companies disclosed concentratedly products included/renewed (恒瑞医药 (Hengrui Medicine): 3 first-time inclusions + 7 renewals; 百利天恒 (Baili Tianheng): iza-bren included in its first launch year; 君实 (Junshi) Touyi new indication, etc.) Announcement Innovative drugs A JRJ
3 11-13 evening Company announcement 源杰科技 (Yuanjie Technology, 688498) won a RMB 1.744 billion high-power laser-diode chip order from Customer B (ex-tax) Orders Optical chips A CLS
4 11-12~15 Reuters / Caixin et al. Jensen Huang resigned as NVIDIA CEO/president/director; CFO takes over on an interim basis; NVIDIA -13% for the week (largest weekly drop since April 2025), down six consecutive weeks; employee petition for his return; Asian supply-chain worries brewing Overseas industry (negative) Computing-power chain / semiconductors A (negative) TMTPost、JW View (US close)
5 11-13 (Friday) US close Dow +0.10%, S&P -0.40%, Nasdaq -0.91%; SOX -3.43%, AMD -8%, SanDisk/WDC -5%, Broadcom/ARM -4% Overseas (negative) Semiconductors / storage / computing power A (negative) Jin10
6 11-15 CCTV / The Paper Iran's Revolutionary Guard 6 drones attacked the radar of the US military base in Riffa, Bahrain; Iran warned of expanding strikes to US bases in Europe; Bahrain intercepted multiple aerial targets Event Oil & gas / oil shipping / defense A The Paper、CLS
7 11-13 Ministry of Commerce First meeting of the trade council under the China-US economic and trade consultation mechanism: discussions on tariffs, "USD 30 billion vs 30 billion" reciprocal tariff cuts, agricultural trade exchanges Macro Broad market / export chain / rare earths A CLS weekend roundup
8 11-15 Company announcement 中国稀土 (China Rare Earth, 000831) plans to issue shares to buy 51% of Zhongxi (Liangshan) Rare Earth (issue price RMB 39.41/share); resumes trading 11-16; target asset is the Maoniuping rare earth mine, whose 2025 net profit of RMB 819 million is 4.75x the listed company's Restructuring Rare earths B+ Company announcement (via NBD)
9 11-15 Company announcement TCL 中环 (TCL Zhonghuan, 002129) plans to acquire 65.8% of Zhonghuan Advanced (No. 1 in China in semiconductor silicon wafer shipments/revenue); resumes trading 11-16 Restructuring Semiconductor silicon wafers B CLS
10 11-15 Company announcement 游族网络 (Yoozoo Network, 002174) subsidiary won a RMB 1.428 billion flash-memory particle procurement order; announcement explicitly states "revenue recognized on a net basis, negligible impact on current-period revenue" Orders (cooling) Storage trading B 10jqka
11 11-15 early morning Riot Games / media BLG beat GEN 3:1 to win the League of Legends S16 championship; LPL champions again after five years, "one run through four" LCK teams; Bilibili giving all members premium membership Event Gaming / esports / media B+ Eastmoney
12 11-14 CINNO (via CLS) December TV panel structural slight price increase: 55-85 inch panels up USD 1-2, other sizes flat Pricing Panels C+ CLS weekend roundup
13 11-14 NDRC / National Energy Administration "15th Five-Year" new-type energy storage implementation plan: guiding storage battery companies to build capacity rationally and orderly, guarding against blind expansion Policy (bearish) Energy storage / lithium batteries B (negative) CLS weekend roundup
14 11-14 CSRC Wu Qing: deepen research on the long-term market-stability mechanism; study and evaluate quantitative trading, share-reduction and other system optimizations Regulation Broad-market sentiment B (warm) CLS weekend roundup
15 11-16 publication Qiushi Xi Jinping's "Building an Asia-Pacific Community with a Shared Future"; APEC CEO Summit with 115 Fortune Global 500 companies participating, US firms nearly 20% of foreign participants Macro Broad market / going global B CLS weekend roundup
16 announced 11-03 / effective 11-15 PBOC FX reserve requirement ratio 4%→6% (announced 11-03, effective 11-15, to dampen RMB appreciation expectations; limited direct impact on A-share liquidity); RMB 200 billion outright reverse repo rolled at a smaller size (net drain of RMB 100 billion); October M2 +7.1% (October data) Liquidity Broad market B (neutral) CLS weekend roundup
17 11-14 Shanghai Stock Exchange Key monitoring of high-premium funds such as the global-chip LOF; self-disciplinary measures on 95 abnormal trading cases Regulation Chips / sentiment B (negative) CLS weekend roundup
18 11-15 Company announcement 天普股份 (Tianpu, 605255, 4 consecutive limit-ups) suspended for verification from 11-16; 金辰股份 (Jinchen, 603396, 3 limit-ups) risk warning: unrelated to reports about SINGULUS SOLAR, no substantive business dealings Regulation / sentiment Short-term height B (negative) CLS weekend roundup
19 11-14 Caixin Weekly Over the week to 11-13, WTI/Brent fell 14%-18% from end-October; global crude supply back in surplus; after the 11-15 attack, Brent grey market only +0.38% (Friday intraday USD 93.99) Pricing (negative) Oil & gas B (negative) Caixin Weekly
20 11-14 Industry China's 10-tonne-class electric commercial aircraft CE-25A made its first crewed flight (COMAC + CATL et al.); SpaceX Starship's first "chopsticks-catching" (upper stage) success Event Low-altitude / commercial spaceflight C CLS weekend roundup
21 11-14 US Labor Department US October PPI +6.5% YoY, below the 6.6% expected (sticky inflation; limited guidance for the Fed's rate-cut path) Macro US stocks / US Treasuries C CLS weekend roundup
22 11-14 Silver Institute Global silver supply to run a deficit for a sixth consecutive year (gap of 35 million oz), but photovoltaic silver demand expected to fall 21% Pricing Silver C CLS weekend roundup
23 11-13 Company announcement 天孚通信 (Tianfu Communication, 300394) cumulatively bought back 500,000 shares for RMB 65.50 million (to be cancelled) Announcement Optical communications C Jiemian

Note: item 15's release time is "11-16 publication" (Qiushi magazine); all other items are within the time window.

2. Strongest Positive Branches, Descending

Rank Branch Strength Core news Logic hardness Durability Beneficiary path Representative stocks Risks
1 Innovative drugs (medical-insurance dual catalogues) ★★★★☆ 51 first-class innovative drugs into medical insurance a record high, CAR-T entering medical insurance for the first time, 19 A-share pharma companies disclosing concentratedly Hard (official catalogue + company announcements, double confirmation) Medium (effective 2027-01-01; short-term sentiment-driven, mid-term hinges on volume-for-price) Payment-side expansion → volume; BD going-global logic strengthened 恒瑞医药 (600276) 、百利天恒 (688506) 、君实生物 (688180) 、复星医药 (Fosun Pharma, 600196) Inclusion = price cuts, almost no current-period earnings contribution; profit-taking on Monday's gap-up; reimbursement scope generally narrowed
2 Oil & gas defense (Middle East event + dividends) ★★★★ Iran's 11-15 attack on the US military base in Bahrain, escalation Medium (event real, but oil prices muted: grey market only +0.38% after the attack, against a supply-surplus backdrop) Short-medium (event position, exit on ceasefire) Oil prices / risk aversion → production dividend defense + oil-shipping elasticity 中国海油 (CNOOC, 600938) 、中远海能 (COSCO Shipping Energy, 600026) 、中海油服 (COSL, 601808) Oil prices already fell 14-18% over two weeks, muted geopolitical transmission; exit as soon as the event de-escalates
3 Gaming / esports / AI short drama (running theme) ★★★☆ BLG wins S16 championship (LPL champions again after five years), fermenting across the internet over the weekend; Friday's AI short drama / cinema was the only survivor on the ice-point day Medium (sentiment hard, earnings chain long) Short (sentiment theme; watch low-position 1-to-2 ladder) Event heat → gaming attention + esports derivatives; AI comic-drama cost-reduction narrative 恺英网络 (Kaiying Network, 002517) 、文投控股 (Wentou Holdings, 600715, high-flag risk) 、金逸影视 (Jinyi Cinema, 002905) 、横店影视 (Hengdian Entertainment, 603103) Overall leader Wentou Holdings 18 days 10 limit-ups has itself disclosed AI comic-drama revenue share of only ~2.57%; high-position relay in a sentiment ebb = catching the falling knife
4 Optical chips (Yuanjie's big order) ★★★ Yuanjie's RMB 1.744 billion order ≈ 108% of 9M26 revenue Hard (company announcement) Medium (delivery mostly after 2027) Direct order → earnings elasticity; high-power CW/EML benefiting from AI optical modules 源杰科技 (688498) Friday single-day -11.76%, PE (TTM) ~75x, anonymous Customer B, optical-communication sector in third day of ebb
5 Rare earths (restructuring + China-US) ★★☆ China Rare Earth resumes trading to acquire 51% of Zhongxi (Liangshan) (target 2025 net profit RMB 819 million); first trade-council meeting continues Medium (announcement real, pricing undetermined) Medium (injection landing; export-control suspension expired 11-10, resumption uncertain either way) Asset injection accretion + rare-earth price cycle 中国稀土 (000831) 、北方稀土 (Northern Rare Earth, 600111) PE (TTM) ~130x; if rare-earth prices fall, target-earnings estimates must be cut; most likely one-way sealed / excessive gap-up
6 Semiconductor silicon wafers (Zhonghuan resumes) ★★ TCL Zhonghuan acquires 65.8% of Zhonghuan Advanced (No. 1 in China in wafers) Medium (announcement real, but small accretion) Medium Minority stake consolidated into parent, direction positive TCL 中环 (002129) PV main business 9M26 loss of RMB 4.557 billion, debt ratio 73.4%; good news drowned by losses
7 Panel price increases ★★ CINNO: December 55-85 inch panels up USD 1-2 Medium (institution forecast) Weak (small magnitude) Expectation of price-hike letters landing 京东方 A (BOE A, 000725) 、 TCL 科技 (TCL Technology, 000100) Increase of USD 1-2 per panel, limited elasticity; continuation of old news, not a new catalyst
8 Low-altitude / commercial spaceflight / silver / AI home appliances ★ CE-25A first flight, Starship chopsticks catch, silver deficit, AI home appliances in introduction phase Weak (remote mapping / weak data) Weak Concept mapping — High probability of a one-day pop, do not chase

Branch notes: why Innovative drugs ranks first — it is the only new catalyst of the weekend with "official document + batch of company announcements" double confirmation, and the sector was previously oversold (pharma was still being sold on Friday), with enough capacity for large funds; but do remember the catalogue takes effect only in 2027, so Monday's move is essentially a valuation repair on "access certainty + payment expansion", not current earnings — the risk of a gap-up-then-fade is real. Oil & gas ranks second because it was the only direction validated by funds on Friday (CNOOC +2.05%, COSL +0.41%), and the weekend escalation gave it continuity, but muted oil prices (grey market +0.38% after the attack, supply surplus) mean it can only be a defensive position, not an offensive one. Gaming / short drama is a "running theme" — Friday's recap lesson requires covering already-running ladders pre-market: Wentou Holdings (600715) with 10 limit-ups in 18 days is a sentiment-top signature; branch opportunities lie in low-position 1-to-2 moves and real-earnings gaming catch-ups, not at high positions. Optical chips is a typical "single-stock logic vs sector headwind" gamble; no matter how real Yuanjie's order is, the auction must confirm whether funds pick the stock or kill the sector. Sector distribution: innovative drugs concentrated on the main board (Hengrui/Fosun) and STAR Market (Baili Tianheng/Junshi/Heyuan, mind the -U unprofitable flag); oil & gas all main board; gaming mostly main board; optical chips / silicon wafers are high-volatility STAR/ChiNext names; no key Beijing Stock Exchange targets today.

3. Stock Positive-Strength Overall Ranking

Rank Code Name Board Branch Level Score Core news Path Directness Fundamentals / industry position Expectation gap Technicals / sentiment Risks Conclusion
1 600276 恒瑞医药 Shanghai main board Innovative drugs A 69 3 first-time inclusions + expanded indications + 7 renewals (involving drugs with RMB 6.951 billion 2025 sales) Access → volume Direct (but effective 2027) Absolute innovative-drug leader, 9M26 net profit +20.4%, cash RMB 43.4 billion, debt ratio 12% Medium (mostly priced in) Oversold + large institutional capacity Static PE ~41x; profit-taking on gap-up priority deep-dive
2 688498 源杰科技 STAR Market (±20%) Optical chips A 65 RMB 1.744 billion order ≈ 108% of 9M26 revenue Direct order → earnings Direct Scarce optical-chip IDM leader, 9M26 revenue +320% / net profit +867% Medium (Customer B identity + delivery cadence undetermined) Friday -11.76% plunge before the good news, huge disagreement PE (TTM) ~75x; sector ebb; anonymous customer watch closely (auction decides)
3 600938 中国海油 Shanghai main board Oil & gas A- 63 Middle East escalation + Brent USD 94 + TTM dividend yield ~4.2% Oil-price elasticity + defense Indirect (earnings already materializing, event kicker) Low-cost leader, 9M26 net profit +16.8%, PE (TTM) ~10.5x Low-medium (already +2.05% on Friday) Only big-cap volume gain closing green on Friday's ice-point day Supply surplus, oil-price pullback priority deep-dive (defense)
4 000831 中国稀土 Shenzhen main board Rare-earth restructuring A- 62 Acquiring 51% of Zhongxi (Liangshan), target 2025 net profit RMB 819 million (4.75x the listed company) Asset injection accretion Direct (pricing TBD) Medium/heavy rare-earth smelting & separation platform, 9M26 net profit +112%; debt ratio only 9.8% Medium (valuation/pricing not out) Resuming after 2-week suspension, most likely one-way sealed / big gap-up PE (TTM) ~130x; rare-earth price cycle watch closely (watch only if gap-up too large)
5 688506 百利天恒 STAR Market (±20%) Innovative drugs A- 57 iza-bren, world's first bispecific ADC, included in medical insurance in its first launch year; BMS license up to USD 8.4 billion Access catalyst + BD monetization Indirect (earnings variable hinges on BMS milestones) Top-tier global FIC pipeline; but 9M26 operating cash flow -RMB 2.168 billion, debt ratio 59.1% Medium (narrow indication scope) Highest-elasticity innovative-drug target Unprofitable, fast cash burn, market cap RMB 103.2 billion watch closely
6 002517 恺英网络 Shenzhen main board Gaming B+ 57 BLG championship + "Blazing Awakening" contributing ~RMB 3.2 billion revenue in 9M26 Sentiment + real earnings Indirect Real gaming earnings: 9M26 revenue +78% / net profit +31%, PE (TTM) ~14x Medium (Friday -1.9%, unmoved) Gaming catch-up position, cash flow RMB 2 billion Single hit title ~44% of revenue (estimate); Q3 revenue up but profit not watch closely
7 600026 中远海能 Shanghai main board Oil shipping B+ 56 Middle East escalation → VLCC rate risk premium Rate elasticity Direct (event-sensitive) One of the world's largest tanker fleets, 9M26 net profit +172%, PE (TTM) ~10.3x Medium (already -2.21% and abandoned on Friday) Elasticity position, unvalidated Friday Rate pullback from highs risk; debt ratio 47.7%; needs double confirmation watch only
8 688180 君实生物 STAR Market (±20%) Innovative drugs B+ 54 Touyi: all 13 indications included in medical insurance (most complete domestic PD-1 coverage) Volume-for-price continuation Direct (materializing) 9M26 revenue +39%, loss narrowing, operating cash flow turned positive Low-medium Loss-making stock, weaker elasticity than Baili Still loss-making; debt ratio 59.6% watch only
9 601808 中海油服 Shanghai main board Oilfield services B+ 48 Offshore oilfield services, benefiting from industry capex Day-rate transmission Indirect (longest chain) 9M26 net profit only +0.7%, cash flow weakening Low Friday +0.41% resilient Revenue up but profit not; dividend yield only ~2.3% watch only
10 600196 复星医药 Shanghai main board Innovative drugs B 45 5 drugs included (Hanshuang first inclusion); involved drugs 2025 sales RMB 2.234 billion (~5% of revenue) Access → moderate volume Indirect (elasticity diluted) PE ~18x, PB ~1.2x; goodwill RMB 10.76 billion Low Low-valuation defensive position Goodwill impairment; tight short-debt structure watch only
11 002129 TCL 中环 Shenzhen main board Semiconductor silicon wafers B 45 Acquiring 65.8% of Zhonghuan Advanced (No. 1 in China in wafers) Parent-net-profit accretion Indirect (small magnitude) PV main business 9M26 loss of RMB 4.557 billion, debt ratio 73.4% Low Resumption event Good news drowned by main-business losses; dilution watch only
12 002555 三七互娱 Shenzhen main board Gaming B 43 BLG championship sentiment mapping Sentiment Indirect Leader but 9M26 ex-non-recurring ~-47%, Q3 single-quarter loss Low Weakening trend User-buying model under pressure; cash flow -60% watch only
13 688765 禾元生物 STAR Market (-U unprofitable, ±20%) Innovative drugs B 37 World's first rice-derived recombinant human albumin included in medical insurance 0-to-1 access Direct but negligible magnitude 9M26 revenue only RMB 28 million; cash runway to be validated Low (already +8.8% front-running Friday) High-expectation small cap No current earnings; continued losses watch only
14 002174 游族网络 Shenzhen main board Storage trading + gaming C+ 32 RMB 1.428 billion flash order (net method) + gaming attribute Buy-sell spread Extremely weak (announcement self-cooling) Main business 2025 loss of RMB 347 million, Q3 single-quarter loss RMB 111 million, 9M cash flow -RMB 650 million Medium (dual concept easily speculated) Concept mash-up Advance-payment trading risk; consecutive losses Pass
15 002148 北纬科技 Shenzhen main board Gaming / communications C 20 3-limit-up height flag (gaming label) Pure sentiment None 9M26 net profit only RMB 5.92 million, PE (TTM) ~7700x (Tencent quote basis, market cap RMB 4.44 billion / TTM net profit ~RMB 5.76 million), negative cash flow Low Height banner after Tianpu's suspension Q3 profit -60%; relay = catching the knife Pass (sentiment weathervane only)

Not on the list but worth knowing: Wentou Holdings (600715, 10 limit-ups in 18 days, sentiment top, watch only), Jinchen (603396, risk-warning announcement, Pass), Tianpu (605255, suspension verification), Northern Rare Earth (600111, rare-earth follow-on), Jinyi Cinema (002905) / Hengdian Entertainment (603103) / China Film (600977, low-position 1-to-2 cinema watch pool).

4. Stock Scoring Model

Total 100 = news-source authority (0-15) + directness of benefit (0-20) + earnings elasticity (0-15) + industry position & fundamentals (0-15, SEPA reference: revenue / net profit / gross margin / cash flow / debt ratio / moat / niche leadership) + expectation gap (0-10) + theme durability (0-10) + A-share trading attributes (0-10) - risk deduction (0-15).

Rank Name (Code) Source authority Directness Earnings elasticity Position / fundamentals Expectation gap Theme durability Trading attributes Risk deduction Total
1 恒瑞医药(600276) 15 14 12 12 5 8 7 -4 69
2 源杰科技(688498) 15 18 13 11 6 6 6 -10 65
3 中国海油(600938) 12 12 10 12 5 7 8 -3 63
4 中国稀土(000831) 15 14 11 11 6 6 6 -7 62
5 百利天恒(688506) 15 11 10 9 6 7 6 -7 57
6 恺英网络(002517) 13 8 8 12 6 6 8 -4 57
7 中远海能(600026) 12 12 11 10 5 6 7 -7 56
8 君实生物(688180) 15 12 9 7 5 6 6 -6 54
9 中海油服(601808) 12 9 7 8 4 6 6 -4 48
10 复星医药(600196) 15 8 6 7 4 5 5 -5 45
11 TCL 中环(002129) 15 9 6 6 5 6 6 -8 45
12 三七互娱(002555) 13 7 6 6 4 5 7 -5 43
13 禾元生物(688765) 15 8 5 4 4 4 5 -8 37
14 游族网络(002174) 14 4 3 3 5 4 7 -8 32
15 北纬科技(002148) 8 3 3 2 4 4 6 -10 20

5. Top 10 Stocks in Detail

51 恒瑞医药600276Overall No. 1, priority deep-dive · Hengrui Medicine · Shanghai main board

  • Related news: Announcement on the evening of 11-15: 3 drugs (泽美妥司他片 zemaitostate tablets, 鲁兹诺雷钠片 luzhinore sodium tablets, 恒格列净瑞格列汀二甲双胍缓释片(II)) included in medical insurance for the first time; 瑞康曲妥珠单抗 (Ruikang trastuzumab) reimbursement indication expanded; 达尔西利 (Darsirib) renewed + new indication added; plus 7 renewals; combined 2025 sales of the above drugs ~RMB 6.951 billion, ~RMB 6.860 billion for the first three quarters of 2026 (CLS、JRJ).
  • Positive logic: Direct positive but mostly already priced in. Medical-insurance negotiation trades price for volume; the new catalogue takes effect only on 2027-01-01, contributing almost nothing to 2026 current-period earnings; for renewed products it is price continuation, for the 3 first-time inclusions it is an access catalyst. What moves is valuation and sentiment, not the current-quarter report.
  • Industry-branch stage: Innovative-drug payment-side expansion is a mid-term narrative (second year of the commercial-insurance catalogue, dual-catalogue linkage); currently at the early fermentation stage of a "policy-event-driven" move, with no limit-up ladder and no core-heavyweight sentiment premium — Hengrui itself is the core heavyweight.
  • Fundamentals check: Absolute innovative-drug leader. 2025 revenue RMB 31.629 billion (+13.0%), net profit attributable to parent RMB 7.711 billion (+21.7%); first three quarters of 2026 revenue RMB 24.409 billion (+5.3%), net profit attributable to parent RMB 6.923 billion (+20.4%), Q3 single-quarter net profit +88.9%; gross margin 86.8%, cash RMB 43.45 billion, debt ratio 12.2%, 9M operating cash flow +RMB 7.844 billion; innovative-drug revenue already over 60%. Healthiest balance sheet on the entire list.
  • Industry position: Overall innovative-drug leader (pipeline breadth + BD monetization both top tier, 2025 BD revenue RMB 3.392 billion).
  • Technicals / sentiment: Main board ±10%; sold off with pharma on Friday, at an oversold position; market cap ~RMB 319 billion, largest institutional capacity, suitable for large funds both defensive and offensive. Note that STAR peers (Baili Tianheng/Junshi) gapping up excessively on 20cm could divert main-board funds.
  • Final call: priority deep-dive. Weekend announcement confirmed + leader + hardest financials, the most tradable target in the innovative-drug branch; but "sell the good-news realization" is the historical pattern of medical-insurance-catalogue moves — if it gaps up over 3% at auction and shows no absorption within 30 minutes, downgrade to watch only.

52 中国海油CNOOC / 600938Overall No. 3, priority deep-dive (defense) · Shanghai main board

  • Related news: On 11-15, Iran's 6 drones attacked the radar of the US military base in Riffa, Bahrain; Iran warned of expanding strikes to US bases in Europe (The Paper); but Brent's grey market was only +0.38% after the 11-15 attack, and Caixin reported on 11-14 that global crude supply is back in surplus, with WTI/Brent down 14%-18% last week from end-October (Caixin Weekly).
  • Positive logic: Indirect (event kicker) + direct (earnings already materializing). Oil-price elasticity flows straight into the report: 9M26 net profit +16.8% mainly benefited from the Brent price center moving up vs 2025 (~USD 70) — note "USD 94" is the YTD-average basis, and the spot price has already fallen 14-18% from end-October (Caixin Weekly); the two are not contradictory; the Middle East conflict provides a sentiment premium, not a supply-demand shock.
  • Industry-branch stage: The oil & gas chain showed "internal divergence, defensive position established" on Friday: CNOOC (600938) +2.05% was the only decent gain among big caps, 岳阳兴长 (Yueyang Xingchang, 000819) limit-up, while the oil-shipping elasticity position COSCO Shipping Energy (600026) -2.21% was abandoned — the branch is in "divergence", not "main upward wave".
  • Fundamentals check: 2025 revenue RMB 398.2 billion, net profit attributable to parent RMB 122.08 billion; first three quarters of 2026 revenue RMB 355.6 billion (+13.8%), net profit attributable to parent RMB 119.12 billion (+16.8%); per-barrel cost in the industry's lowest tier; PE (TTM) ~10.5x; dividend per share ~RMB 1.292 over the past 12 months (2025 final RMB 0.4788 + 2026 interim RMB 0.8132), a TTM dividend yield of ~4.2% vs Friday's close of RMB 30.85 (trailing-12-month dividend basis, Eastmoney dividend interface). Thickest financial and valuation safety cushion on the list.
  • Industry position: Absolute leader in offshore oil & gas production (market cap ~RMB 1.47 trillion).
  • Technicals / sentiment: Main board ±10%; on Friday's ice-point day a RMB 1.44 trillion market cap closed green on volume, the real destination of funds rotating to low positions; if the auction stays strong on Monday, its "defensive core heavyweight" status is confirmed.
  • Final call: priority deep-dive (defensive position). In an ebb period and ahead of NVIDIA earnings, its "~10.5x + ~4.2% dividend" combo is the ballast; the risk is the supply-surplus oil logic — it loses elasticity as soon as the event cools. It is a "hold for the dividend and pocket the event money" stock, not an offensive stock.

53 源杰科技688498Overall No. 2, watch closely · Yuanjie Technology · STAR Market · ±20%

  • Related news: Announcement on the evening of 11-13: won a RMB 1.744 billion (ex-tax) high-power laser-diode chip order from Customer B (CLS); the stock fell -11.76% single-day on Friday to close at RMB 673.10, market cap ~RMB 82.7 billion; the market speculates Customer B is related to the overseas computing-power chain, but the company exempted disclosure of the customer identity under confidential procedures — "related to the overseas computing-power chain" is market speculation, not an announcement fact.
  • Positive logic: Direct order positive, huge elasticity. RMB 1.744 billion ≈ 108% of 9M26 revenue (RMB 1.609 billion), 2.9x full-year 2025 revenue; the company announced two capacity expansions in 2026 totaling over RMB 5.5 billion (Aug: RMB 4.268 billion semiconductor industrial park + Feb: RMB 1.251 billion base phase II, Sina Finance), and the Q3 earnings call said "end customers may also become direct customers in the future", pointing to high-power CW/EML light sources for AI optical modules — but delivery is mostly after 2027, so the elasticity lands far out.
  • Industry-branch stage: The optical communications / optical module sector overall is in the third day of ebb (Friday: 中际旭创 (Zhongji Innolight, 300308) -8.39%, 新易盛 (Eoptolink, 300502) -8.76%, 天孚通信 (300394) -10.94%); Yuanjie is a lone case of "single-stock logic against sector trend"; no ladder, no follower limit-ups — it is a standalone order-driven move.
  • Fundamentals check: Scarce optical-chip IDM leader (one of few in China mass-producing 25G/100G EML; high-speed optical chips previously monopolized by Lumentum/Broadcom). 2025 revenue RMB 601 million (+138.5%), net profit attributable to parent RMB 191 million; first three quarters of 2026 revenue RMB 1.609 billion (+319.8%), net profit attributable to parent RMB 1.024 billion (+866.9%), gross margin 81.7%; data-center revenue RMB 774 million in 2026H1 (+640%). Genuinely rapid reported growth; hidden concerns are accounts receivable +151.7% YoY and PE (TTM) ~75x.
  • Industry position: Niche leader (a scarce A-share optical-chip design + IDM name, "the former stock king").
  • Technicals / sentiment: STAR Market ±20%; a big-volume -11.76% plunge on Friday followed by good news, huge long-short disagreement; Monday's auction is the showdown between "order logic beats sector ebb" and "good-news distribution".
  • Final call: watch closely (auction decides). Gap up 3%+ and hold above Friday's low for 30 minutes with active volume → order logic holds; open lower or turn green-negative 15 minutes after a gap-up → the sector drag wins, delete. 75x PE + anonymous customer do not support chasing; only right-side follow after auction confirmation.

54 中国稀土000831Overall No. 4, watch closely · China Rare Earth · Shenzhen main board

  • Related news: Announcement on 11-15: plans to issue shares to purchase 51% of Zhongxi (Liangshan) Rare Earth and raise supporting funds, issue price RMB 39.41/share (~17% discount to the RMB 47.59 pre-suspension price), resumes trading 11-16; the target's core asset is the Maoniuping rare earth mine (REO ~11.46 million tonnes, No. 2 in China for light rare earths), net profit RMB 511/819/674 million in 2024/2025/2026H1 (NBD).
  • Positive logic: Direct (asset injection accretion). The target's 2025 net profit is 4.75x the listed company's (RMB 173 million); the 51% stake corresponds to an annual net-profit contribution of ~RMB 420 million+, a major accretion; it is also the group's move to honor its 2027 commitment to resolve horizontal competition. The first trade-council meeting (11-13) keeps communication going; the rare-earth export-control suspension (to 2026-11-10, per the Ministry of Commerce's April statement, Sina Finance) has expired — whether controls resume (bullish for domestic price expectations, bearish for export volumes) or talks extend is a two-way scenario with an undetermined direction; do not trade it as one-way bullish.
  • Industry-branch stage: Rare earths have no running limit-up ladder; this is a "restructuring-resumption event-driven" move; Northern Rare Earth (600111) is the sector core heavyweight.
  • Fundamentals check: Listed company 2025 revenue RMB 3.182 billion, net profit attributable to parent RMB 173 million (turnaround, +160%); first three quarters of 2026 net profit attributable to parent RMB 408 million (+112%), but the Q3 single-quarter +461.7% relies mainly on rare-earth price rises plus reversal of inventory write-down provisions (earnings quality needs a discount); debt ratio only 9.8%, 9M operating cash flow +RMB 674 million (+469%). Expensive valuation: PE (TTM) ~130x, PB ~9.7x.
  • Industry position: Listed platform for medium/heavy rare-earth smelting & separation; after the injection it becomes an integrated "mining-beneficiation-smelting-processing" player.
  • Technicals / sentiment: Main board ±10%; suspended for 2 weeks + no new rare-earth negative news over the weekend, so resumption is most likely one-way sealed or gap up over 7%; if the gap-up is excessive (e.g. 8%+ with the seal opening on huge volume), downgrade directly to watch only — the first bite of a restructuring resumption usually cannot be had and must not be chased.
  • Final call: watch closely. The assets are real and the accretion is real, but 130x PE + undetermined pricing + the rare-earth price cycle make triple uncertainty; it is only worth participating if "strong absorption after the seal opens and sector follows (Northern Rare Earth volumes up)"; otherwise just watch.

55 百利天恒688506Overall No. 5, watch closely · Baili Tianheng · STAR Market · ±20%

  • Related news: Announcement on 11-15: the world's first EGFR×HER3 bispecific ADC (iza-bren/宜泽康® Yizekang, approved in June) was included in the 2026 medical-insurance catalogue in its first launch year via the "pre-declaration" mechanism, reimbursement limited to recurrent/metastatic nasopharyngeal carcinoma after failure of at least second-line chemotherapy and PD-1/PD-L1 therapy (CLS).
  • Positive logic: Indirect + access catalyst. The medical-insurance reimbursement scope is narrow (single nasopharyngeal-carcinoma indication), with small impact on current-period revenue; the real earnings variable is the cadence of BMS-license milestones (2023-12 agreement framework up to USD 8.4 billion; by 2025-10, upfront + milestones of over USD 1 billion already recognized, Tencent News) and global Phase III data. First-year medical-insurance inclusion raises the certainty of domestic commercialization.
  • Industry-branch stage: In sync with the innovative-drug branch; the high-elasticity target (STAR 20cm).
  • Fundamentals check: 2025 revenue RMB 2.520 billion (-56.7%), net profit attributable to parent -RMB 1.054 billion; first three quarters of 2026 revenue RMB 2.094 billion (Q3 single-quarter ~RMB 1.9 billion, inferred to be the BMS milestone payment — this inference is not confirmed by the company and needs verification), net profit attributable to parent -RMB 705 million; 9M R&D expense RMB 2.045 billion (98% ratio); operating cash flow -RMB 2.168 billion, debt ratio 59.1%, burning cash and reliant on continued BMS payments. Market cap ~RMB 103.2 billion.
  • Industry position: The only listed global FIC bispecific ADC, highest pipeline deliverability in the innovative-drug group (BD cash flow as backing).
  • Technicals / sentiment: STAR Market ±20%; if innovative drugs ferment, it is the highest-elasticity target; unprofitable + highly leveraged means extreme volatility.
  • Final call: watch closely. Buying it is buying the combination of "global FIC + medical-insurance access + BMS monetization", not current earnings; only a 10%+ auction gap-up that does not fade within 15 minutes shows fund recognition — otherwise wait for a pullback.

56 恺英网络002517Overall No. 6, watch closely · Kaiying Network · Shenzhen main board

  • Related news: On 11-15 BLG beat GEN 3:1 to win the League of Legends S16 championship, LPL champions again after five years, Bilibili giving all members premium membership (Eastmoney); the gaming branch was Friday's only survivor alongside AI short drama.
  • Positive logic: Indirect (industry sentiment) + direct (own earnings). The esports championship lifts sector attention and sentiment, but Kaiying itself does not depend on this event — its logic is "gaming-branch catch-up + real earnings": "Blazing Awakening" contributed ~RMB 3.2 billion revenue in 9M26 (Phoenix Finance citing company financials), and "Three Kingdoms: Tianxia Guixin" launched in October.
  • Industry-branch stage: Gaming/media is a "running theme": Wentou Holdings (600715) with 10 limit-ups in 18 days is the sentiment top; Kaiying -1.90% on Friday, a low-position catch-up spot.
  • Fundamentals check: 2025 revenue RMB 5.325 billion, net profit attributable to parent RMB 1.904 billion (+16.9%); first three quarters of 2026 revenue RMB 7.258 billion (+78.1%), net profit attributable to parent RMB 2.069 billion (+30.7%), gross margin 76.7%, operating cash flow RMB 2.002 billion; PE (TTM) ~14.3x. Note Q3 single-quarter net profit only +1.22% (early sign of revenue-up-profit-not), and "Blazing Awakening" ~RMB 3.2 billion ≈ 44% of first-three-quarter revenue (32/72.58 estimate).
  • Industry position: Gaming sector's best on both earnings and valuation (niche leader).
  • Technicals / sentiment: Main board ±10%; no consecutive-limit-up baggage, institutions can hold; if gaming ferments on Monday, it is the stock you "can board" (Wentou/Beiwei are not boardable).
  • Final call: watch closely. If the branch holds (Wentou no nuclear button + low-position 1-to-2 appear), it is the gaming branch's first choice; if not, it falls back to the ~14x PE earnings floor, with controllable downside.

57 中远海能600026Overall No. 7, watch only · COSCO Shipping Energy · Shanghai main board

  • Related news: Same as CNOOC (Middle East event); oil shipping is the most direct elasticity play on the Middle East situation (VLCC rate risk premium).
  • Positive logic: Direct (event-sensitive). Middle East tension → Strait of Hormuz transit risk + shadow-fleet sanctions → effective capacity contraction → rate elasticity; 2026 earnings already materializing (9M26 net profit +171.9%).
  • Fundamentals check: 2025 revenue RMB 23.89 billion, net profit attributable to parent RMB 4.04 billion; first three quarters of 2026 revenue RMB 25.24 billion (+47.0%), net profit attributable to parent RMB 7.39 billion (+171.9%), gross margin 40.8%; PE (TTM) ~10.3x, TTM dividend yield ~4.0%; debt ratio 47.7%, highest in the oil & gas group. Strong cyclical.
  • Technicals / sentiment: Main board ±10%; Friday -2.21% — Friday's recap already characterized "elasticity position abandoned"; recovery needs double confirmation of "gap-up on auction volume + 3 or more sector limit-ups".
  • Final call: watch only. The cleanest logic and biggest elasticity, but Friday funds voted with their feet for the defensive position (CNOOC); if the oil & gas chain really explodes on Monday, it will be the fiercest follower — there will still be time to board then.

58 君实生物688180Overall No. 8, watch only · Junshi Biosciences · STAR Market · ±20%

  • Related news: Announcement on 11-15: Toripalimab (拓益® Touyi) plus disitamab vedotin for HER2-expressing urothelial carcinoma added as a new medical-insurance indication; all 13 indications now included (company announcement).
  • Positive logic: Direct and materializing. PD-1 is ~80% of revenue; the volume-for-price logic has been validated by "9M26 revenue +39.2%, loss narrowing, operating cash flow turning positive"; the new indication is continuation, not a sudden change.
  • Fundamentals check: 2025 revenue RMB 2.498 billion, net profit attributable to parent -RMB 875 million; first three quarters of 2026 revenue RMB 2.513 billion (+39.2%), net profit attributable to parent -RMB 149 million (loss greatly narrowed), gross margin 82.7%; debt ratio 59.6%, low cash/interest-bearing-debt ratio. Unprofitable.
  • Technicals / sentiment: STAR Market ±20%; the "materializing" name within the innovative-drug branch, with elasticity and risk both below Baili Tianheng.
  • Final call: watch only. The materialization is real and the improvement is real, but unprofitable + high leverage make it just an observation sample within the branch; if you must play innovative drugs, main-board Hengrui is steadier and Baili Tianheng has bigger elasticity — Junshi sits in the middle, neither here nor there.

59 中海油服COSL / 601808Overall No. 9, watch only · Shanghai main board

  • Related news: Same as CNOOC; the offshore oilfield-services leader, benefiting from parent and industry capex.
  • Positive logic: Indirect (longest transmission chain): day rates and contracts lag oil prices; 9M26 net profit only +0.7%, revenue up but profit not, the weakest event elasticity among the five oil names.
  • Fundamentals check: 2025 revenue RMB 50.28 billion, net profit attributable to parent RMB 3.84 billion (+22.5%); first three quarters of 2026 revenue RMB 35.73 billion (+2.5%), net profit attributable to parent RMB 3.23 billion (+0.7%); 9M operating cash flow only RMB 1.9 billion (weakening); debt ratio 41.6%; TTM dividend yield ~2.3%. PE (TTM) ~15.2x.
  • Final call: watch only. Steady but bland; Friday +0.41% already reflected "follower" status; for oil & gas exposure just do CNOOC (defense) and COSCO Shipping Energy (elasticity) — oilfield services sits in the middle with neither end.

510 复星医药600196Overall No. 10, watch only · Fosun Pharma · Shanghai main board

  • Related news: Announcement on 11-15: 5 drugs included (Hanshuang/serplulimab first inclusion is the largest marginal addition, Futuoning/Fumaining new reimbursement indications, Fukeshu moved to the regular catalogue); involved drugs 2025 sales RMB 2.234 billion (~5.36% of group revenue) (10jqka citing announcement).
  • Positive logic: Indirect, mildly positive. Involved drugs are only 5% of revenue, and effective only in 2027; at the group level, generic-drug centralized-procurement pressure and investment-income swings are the main earnings variables — the medical-insurance catalyst is almost invisible on the report.
  • Fundamentals check: 2025 revenue RMB 41.662 billion, net profit attributable to parent RMB 3.371 billion (+21.7%); first three quarters of 2026 revenue RMB 30.463 billion (+3.6%), net profit attributable to parent RMB 2.667 billion (+5.7%); goodwill RMB 10.76 billion (~21% of net profit attributable to parent); short-term borrowings RMB 15.49 billion vs cash RMB 13.3 billion; PE ~18x, PB ~1.2x.
  • Final call: watch only. Low valuation + low debt cost form a floor, but innovative-drug elasticity is diluted by the huge base, and goodwill plus short-term debt cap the upside; it is a "bond-like asset" within pharma, not a catalyst asset.

6. Pass List

Code Name Concept Why associated Pass reason Keep watching?
002174 游族网络 Storage trading + gaming RMB 1.428 billion flash order + BLG championship gaming sentiment Announcement explicitly states minimal revenue impact under the net method — just pass-through trading; gaming main business 2025 loss of RMB 347 million, another RMB 111 million single-quarter loss in Q3, 9M operating cash flow -RMB 651 million (advance-payment risk already visible); concept mash-up easily pulled up by quant sentiment, extremely high relay risk Watch (sentiment thermometer only, no relay)
002148 北纬科技 Gaming / short drama 3-limit-up height + gaming ETF holdings PE (TTM) ~7700x; 9M26 net profit only RMB 5.92 million, Q3 -60%, operating cash flow negative for consecutive periods; no substantive revenue from gaming/short drama; after Tianpu's suspension it became the height banner, but fundamentals cannot support a fourth limit-up Weathervane only (its limit-up = sentiment repair, nuclear button = continued ebb)
300528 幸福蓝海 AI short drama / film Friday 20cm limit-up, AI comic-drama narrative Cinema main business ~79% of revenue, first three quarters of 2026 revenue -20%, losses expanded 8x, six consecutive loss-making years, debt ratio ~78%, PB 19x; AI short-drama revenue share negligible (not separately disclosed) Watch (branch sentiment sample, no buying)
600715 文投控股 AI comic-drama overall leader 10 limit-ups in 18 days Company self-disclosed AI comic-drama revenue share of only ~2.57% (unaudited); sentiment-top signature, Friday's recap already said "do not take the last baton of the overall leader" Watch (branch life-or-death signal only)
603396 金辰股份 Photovoltaic / HJT concept 3 limit-ups + SINGULUS report association Company risk warning on the evening of 11-15: unrelated to the reported matters, no substantive business dealings with SINGULUS SOLAR (that subsidiary had zero revenue in Jan-Oct); buyback + TGV glass-substrate packaging concept insufficient support No
002129 TCL 中环 Semiconductor silicon wafer restructuring Resumption + acquiring wafer leader Acquisition real but accretion only ~RMB 100 million-level, a drop in the bucket vs the -RMB 4.557 billion main-business loss (9M26); debt ratio 73.4% rising quarter by quarter; PV wafer gross margin still negative (2026 Q3 gross margin -7.3%); share issuance dilution Watch (no chasing the resumption pop)
605255 天普股份 Auto parts / compute chips 4 consecutive limit-ups Suspended for verification from 11-16, untradable; high catch-down risk after resumption No (no trading value before resumption)
002555 三七互娱 Gaming (BLG sentiment) Gaming leader + championship sentiment 9M26 ex-non-recurring ~-47%, Q3 single-quarter loss of RMB 506 million (including investment swings), operating cash flow -60%; user-buying model entering a pressured stock phase, the championship cannot save the report Watch (sector core-heavyweight reference only)
688765 禾元生物 Innovative drugs (-U) World's first rice-derived recombinant human albumin into medical insurance 9M26 revenue only RMB 28 million, annual losses over RMB 100 million, RMB 1.4 billion construction-in-progress with ongoing capex; the 0-to-1 story is real but there are no current earnings, and it already front-ran +8.8% on Friday Watch (branch sentiment sample only, do not participate)
603366/600327 日出东方 (Sunrise East) / 大东方 (Great East) Mysticism high-flags Earlier consecutive limit-ups Regulatory letter + ebb confirmed; Friday Great East (600327) limit-down; the bounce is an escape window No
— Commercial spaceflight / low-altitude concept Starship recovery / CE-25A first flight SpaceX chopsticks catch + electric aircraft first flight Remote mapping, no direct A-share orders/supply evidence; historically high probability of a one-day pop No
— Energy-storage battery expansion chain 15th Five-Year storage plan Policy release The plan's main tone is "guard against blind expansion, implement lithium-battery industry control" — a constraint on expansion, not encouragement; direction bearish No

7. Intra-Branch Ranking

7.1 Innovative Drugs (Medical-Insurance Dual Catalogues)

Rank Stock Board Role Directness Fundamentals support Trading recognizability Conclusion
1 恒瑞医药(600276) Shanghai main board Core heavyweight / overall leader High (3 first-time inclusions + 7 renewals, involved sales RMB 6.951 billion) Strongest (net profit +20.4%, cash RMB 43.4 billion) Highest (RMB 319 billion capacity) hardest stock, priority deep-dive
2 百利天恒(688506) STAR Market Elasticity leader Medium (FIC access catalyst) Medium (unprofitable, cash flow -RMB 2.17 billion, but backed by BMS USD 8.4 billion) High (20cm) Top elasticity pick, for high risk appetite
3 君实生物(688180) STAR Market Niche fulfiller High (all 13 indications included, materializing) Medium (loss narrowing + cash flow positive) Medium Observation sample
4 复星医药(600196) Shanghai main board Low-valuation defense Low (involved drugs 5% of revenue) Medium (18x PE, goodwill pressure) Medium Bond-like observation
5 禾元生物(688765) STAR Market (-U) Pure expectation Medium (exclusive access) Weak (annual revenue RMB 28 million) Low watch only

Follower note: Zelgen (泽璟制药), Allist (艾力斯), Dizal (迪哲医药) et al. were not verified one by one by this group; if funds scoop them to limit-up at Monday's auction, that is branch follow-on and not recommended in this list. Who Passes: Heyuan Biotech (unprofitable small cap), any target lifted purely on the "innovative drug concept" without an announcement.

7.2 Oil & Gas / Oil Shipping (Middle East Event + Dividends)

Rank Stock Board Role Directness Fundamentals support Trading recognizability Conclusion
1 中国海油(600938) Shanghai main board Defensive core heavyweight Medium (oil-price elasticity, 9M26 net profit +16.8% materializing) Strongest (10.5x / dividend ~4.2%) Highest (RMB 1.47 trillion, Friday's only big-cap volume gain closing green) hardest, defensive first choice
2 中远海能(600026) Shanghai main board Elasticity play High (direct rate beneficiary) Strong (+172%, 10.3x / dividend 4.0%) High watch only, wait for double confirmation
3 中海油服(601808) Shanghai main board Follower Low (longest transmission chain) Medium (+0.7%, revenue up profit not) Medium watch only
— 岳阳兴长(000819) Shenzhen main board Back-row sentiment Low Weak Low (Friday 1 limit-up) Pass (lone seed, no relay)

Followers: Yueyang Xingchang et al. first-limit-up sentiment plays; who Passes: Heshun Petroleum (和顺石油, 603353), Hongtong Gas (洪通燃气, 605169) et al. Friday's broken-limit-up sentiment plays.

7.3 Gaming / Esports / AI Short Drama (Running Theme)

Rank Stock Board Role Directness Fundamentals support Trading recognizability Conclusion
1 恺英网络(002517) Shenzhen main board Real-earnings catch-up Medium (BLG sentiment + own hit title) Strongest (revenue +78% / net profit +31%, 14x) High branch's first-choice tradable
2 文投控股(600715) Shanghai main board Overall leader (sentiment top) Low (self-disclosed revenue share 2.57%) Weak Highest (10 limit-ups in 18 days) watch only, branch life-or-death signal
3 金逸影视(002905)/横店影视(603103)/中国电影(600977) Shenzhen/Shanghai main board Low-position 1-to-2 watch pool Low Cinema fundamentals weak Medium watch, only advance confirms
4 三七互娱(002555) Shenzhen main board Core heavyweight (weakening) Low Weak (ex-non-recurring -47%) Medium watch only

Who Passes: Beiwei Technology (002148, PE 7700x pure sentiment), Xingfu Lanhai (300528, six consecutive loss-making years).

8. Monday Opening Verification Signals

Broad market (top priority): Friday's ice point (advancement rate 19%, 33 limit-downs); Monday's first signal is whether the Shanghai Composite can reclaim 3647 (Friday's breakdown point) and whether ChiNext can stop falling; if the Shanghai Composite opens down over 0.5% and cannot recover within 30 minutes, all branch verification points automatically invalidate — stay in cash and observe. The FX reserve-requirement-ratio hike to 6% taking effect + the reverse repo rolled at a smaller size make liquidity expectations neutral-to-tight.

Auction signals (9:15-9:25):

  • Innovative drugs: the gap-up magnitude of Hengrui (600276) and Baili Tianheng (688506) — gap-up ≤3% with moderate auction volume = healthy; 3 or more pharma limit-ups in the sector (or two 20cm ones) = branch confirmed; Hengrui gap-up 5%+ and turning green-negative before 9:35 = profit-taking dominates, whole branch downgraded.
  • Oil & gas: whether CNOOC (600938) stays strong at auction (green + volume); the Asian-session Brent catch-up move to Saturday's attack (Friday's print 93.99; if the Asian session rises over 2%, the event is being re-priced).
  • Yuanjie Technology (688498): gap-up 3%+ and holding above Friday's low for 30 minutes = order logic wins; open lower or turn green-negative 15 minutes after gap-up = sector drag wins, delete.
  • China Rare Earth (000831): most likely huge one-way orders / big gap-up; seal opening on huge volume is the danger; whether Northern Rare Earth (600111) follows with volume is the branch confirmation signal.
  • Gaming: whether Wentou Holdings (600715) gets the nuclear button at auction (open down 5%+) = whole branch downgraded; Beiwei Technology (002148) 3-to-4 and low-position cinema 1-to-2 (Jinyi Cinema (002905) / Hengdian Entertainment (603103)) are the sentiment-rebuilding signals.

Sector signals: 3 or more fast limit-ups in the same branch = ladder confirmed; core-heavyweight volume (Hengrui / CNOOC / Kaiying) = real money; second/third-limit-up ladder appearing = sentiment repair; yesterday's strong themes (computing power / storage) still leading the decline = the ebb has not ended, new-theme height is capped.

Single-stock signals: absorption in the first 5 minutes, fast limit-up without huge volume, large-order net inflows; being out-positioned by a stronger same-branch stock (e.g. Junshi stronger than Baili) = swap signal.

Risk signals (exit immediately if triggered): ① the computing-power chain opens lower and keeps selling (the mapping of NVIDIA -13% weekly + SOX -3.43% is unfinished; no one catches the falling knife before NVDA earnings Tuesday); ② innovative drugs gap up then fade, all turning green-negative; ③ Iran situation cools (ceasefire / negotiation language) = oil & gas event position exits immediately; ④ Wentou Holdings nuclear button crashes gaming; ⑤ a low-volume index rebound failing at 3647 = a mid-decline continuation.

9. Final Recommendations

① The 5 Most Worthy Stocks Today (sorted by tradeability, not by overall score)

Rank Stock Branch Reason Biggest risk Tomorrow's verification
1 恒瑞医药(600276, Shanghai main board) Innovative drugs Weekend announcement confirmed (3 first-time inclusions + 7 renewals) + absolute innovative-drug leader + 9M26 net profit +20.4% + RMB 43.4 billion cash; the only large-capacity exit for big money on the ice-point day Medical insurance effective only in 2027, sell-the-realization; 41x PE gap-up gets smashed Gap-up ≤3% with 30-minute absorption; 3 or more sector limit-ups
2 中国海油(600938, Shanghai main board) Oil & gas defense ~10.5x + ~4.2% dividend safety cushion, 9M26 net profit +16.8% materializing, Friday's only big-cap volume gain closing green, Middle East event kicker Oil supply surplus, loses elasticity as the event cools Green at auction + Brent holding USD 94 in Asian session; cut exposure if it falls back below 30.5
3 源杰科技(688498, STAR Market ±20%) Optical chips RMB 1.744 billion order = 108% of 9M26 revenue, scarce IDM leader + genuinely rapid earnings growth (+867%) 75x PE + anonymous customer + sector ebb, already -11.76% Friday Auction gap-up 3%+ and holding above Friday's low for 30 minutes, else delete
4 恺英网络(002517, Shenzhen main board) Gaming / esports BLG championship fermenting over the weekend + own "Blazing Awakening" ~RMB 3.2 billion revenue in 9M (Phoenix citing financials), revenue +78% / 14x, unmoved Friday with catch-up room Hit-title concentration ~44% (estimate); one-day gaming sentiment Wentou Holdings (600715) no nuclear button + low-position cinema 1-to-2 appear
5 中国稀土(000831, Shenzhen main board) Rare-earth restructuring Injecting 51% of Zhongxi (Liangshan) (target 2025 net profit RMB 819 million = 4.75x the listed company) + debt ratio only 9.8% + China-US consultation window 130x PE; pricing undetermined; most likely unbuyable or gap-up too large Resumption seal order / absorption after seal opens; Northern Rare Earth (600111) volume follow; gap-up 8%+ with seal opening on huge volume = watch only

Alternate: Baili Tianheng (688506, STAR Market) — the elasticity king of innovative drugs, for high risk appetite after auction confirmation.

② The 3 Strongest Branches Today

Rank Branch Core catalyst Durability Representative stocks
1 Innovative drugs (medical-insurance dual catalogues) 51 first-class innovative drugs a record high + CAR-T first medical-insurance entry + 19 concentrated disclosures Medium (2027 effective; short-term sentiment + mid-term payment expansion) 恒瑞医药(600276) 、百利天恒(688506)
2 Oil & gas defense (Middle East event) Iran's attack on the US military base in Bahrain escalates Short-medium (event position, exit on ceasefire) 中国海油(600938) 、中远海能(600026)
3 Gaming / esports / AI short drama BLG S16 championship + Friday's only survivor continuing Short (sentiment, watch low-position ladder) 恺英网络(002517) 、文投控股(600715, risk)

③ Directions Not to Chase Today

  • The entire computing-hardware chain (optical modules / PCB / servers / storage): NVIDIA CEO resignation + -13% weekly + SOX -3.43%, funds de-risking ahead of NVDA earnings Tuesday; the third day of ebb — do not catch the falling knife (continuation of Friday's recap conclusion).
  • Pure-sentiment high-flags: Wentou Holdings (600715, 10 limit-ups in 18 days + revenue share 2.57%), Beiwei Technology (002148, PE 7700x), Xingfu Lanhai (300528, six consecutive loss-making years) — relay = catching the knife.
  • Yoozoo Network (002174): net-method order does not enter the report + main-business losses + deteriorating advance-payment cash flow; the dual concept is a quant incubator.
  • TCL Zhonghuan (002129): the acquisition good news is real but its magnitude is drowned by the -RMB 4.557 billion main-business loss, 73.4% debt ratio; no chasing the resumption pop.
  • Storage expansion chain: the "15th Five-Year" plan's main tone is guarding against blind expansion — direction bearish.
  • Commercial spaceflight / low-altitude / silver concepts: remote mapping, no direct A-share order evidence, high probability of a one-day pop.

④ Final One-Line Judgment

A "news-driven-repair observation day" after the ice point: Monday's strongest new catalyst is innovative drugs ignited by the medical-insurance dual catalogues (Hengrui as the core heavyweight, Baili Tianheng as the elasticity play); for defensive positioning watch CNOOC's (600938) dividend floor; for sentiment positioning watch low-position gaming catch-up (Kaiying Network); Yuanjie Technology's (688498) RMB 1.744 billion order will be settled by the auction; keep avoiding the computing-power chain until NVDA earnings land, and discount all positions until the Shanghai Composite reclaims 3647.

⚠️ Data-sourcing notes for this report: ① Quotes/financials were pulled this morning by three fundamentals sub-agents via akshare (Eastmoney earnings/dividend interfaces + Tencent/Sina quotes), covering the 2025 annual report + 2026 Q3 report; total market cap is estimated as closing price × total shares. ② Friday's recap recorded Eastmoney push2 sector interface 502 errors and the 龙虎榜 (dragon-tiger list) interface returning None; this report no longer relies on those two interfaces, so dragon-tiger / sector fund-flow data is missing and not included in the body. ③ The recognition nature of Baili Tianheng's Q3 single-quarter revenue of ~RMB 1.9 billion (inferred to be the BMS milestone payment) is not confirmed by the company and is flagged in the body. ④ Brent data-basis discrepancy: Caixin Weekly says WTI/Brent fell 14-18% last week from end-October, while the sub-agent got USD 93.99 intraday on 11-13 + grey market +0.38% after the attack; the body presents both side by side. ⑤ Two corrections after risk-auditor QC: CNOOC total score 66→63 (component-sum arithmetic error, rank swapped with Yuanjie); its TTM dividend yield 6.3%→4.2% (the original basis double-counted the 2025 interim dividend; corrected to trailing 12 months: 2025 final RMB 0.4788 + 2026 interim RMB 0.8132 ÷ RMB 30.85).

⚠️ Risk warning: this list is only a pre-market information roundup and observation aid, and does not constitute investment advice. A-share volatility risk is extremely high; automatically generated content may carry information timeliness gaps or industry-chain mapping errors, and must not be used directly as a trading basis.

Sources22

Every external link cited in the body, numbered in order of appearance. · 16 domains

  1. 1Qiushi.comqstheory.cn
  2. 2JRJfinance.jrj.com.cn
  3. 3CLScls.cn
  4. 4TMTPosttmtpost.com
  5. 5JW View (US close)jwview.com
  6. 6Jin10flash.jin10.com
  7. 7The Paperthepaper.cn
  8. 8CLScls.cn
  9. 9CLS weekend roundupcls.cn
  10. 10Company announcement (via NBD)sfccn.com
  11. 11CLSm.cls.cn
  12. 1210jqkam.10jqka.com.cn
  13. 13Eastmoneywap.eastmoney.com
  14. 14Caixin Weeklyweekly.caixin.com
  15. 15Jiemianm.jiemian.com
  16. 16Sina Financefinance.sina.com.cn
  17. 17Sina Financefinance.sina.com.cn
  18. 18CLScls.cn
  19. 19Tencent Newsnews.qq.com
  20. 20Phoenix Financefinance.ifeng.com
  21. 21company announcementfinance.jrj.com.cn
  22. 2210jqka citing announcementm.10jqka.com.cn